Раціональне застосування антибіотиків при інфекціях дихальних шляхів в амбулаторній практиці

Огляд етіології позалікарняних інфекцій, резистентності збудників до антимікробних препаратів. Аналіз рекомендацій з емпіричної терапії позалікарняних інфекцій дихальних шляхів. Особливості ведення хворих на негоспітальну пневмонію в амбулаторних умовах.

Рубрика Медицина
Вид статья
Язык украинский
Дата добавления 30.12.2017
Размер файла 150,4 K

Отправить свою хорошую работу в базу знаний просто. Используйте форму, расположенную ниже

Студенты, аспиранты, молодые ученые, использующие базу знаний в своей учебе и работе, будут вам очень благодарны.

11. Ball P., Baquero F, Cars O., et al. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 2002; 49 (1): 31-40.

12. Bircan, A., Gokirmak, M., Killic, O., Ozturk, O. and Akkarya, A. C-reactive protein levels in patients with chronic obstructive pulmonary disease: role of infection. Med Princ Pract 2008; 17: P. 202-208.

13. Bjerrum L., Gahrn-Hansen B., Munck A.P. C-reactive protein measurement in general practice may lead to lower antibiotic prescribing for sinusitis // Br. J. Gen. Pract.- 2004; 54: P. 659-662.

14. Bone R.C. Toward an Epidemiology and Natural History of SIRS // JAMA. 1992. Vol. 268. P. 3452-3455.

15. Dellinger R.P., Levy M.M., Carlet J.M. et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008 // Intensive Care Med. 2008. Vol. 34(1). P. 17-60.

16. Feshchenko Y., Dzyublik F., Pertseva T. et al. Antibacterial resis- tanceamong Streptococcus pneumonia and Haemophilus influenza from Ukraine: Results from the Survey of Antibiotic Resistance (SOAR) 2011-2013. Poster presentation (P1589) 24th ECCMID. - Barselona,Spain, 2014. - PMid: 25823339.

17. Fukuda Y., Yanagihara K., Higashiyama Y. et al. Effects of macrolides on pneumolysin of macrolide-resistant Streptococcus pneumoniae // Eur.Respir. J. 2006. Vol. 27(5). P. 1020-1025.

18. Gonzales R., Bartlett J.G,. Besser R.E., et al. Principles of appropriate antibiotic use for treatment of acute respiratory tract infections in adults: background, specific aims, and methods. Ann Intern Med 2001; 134 (6): 479-86.

19. Gonzales R., Steiner J.F., Sande M.A. Antibiotic prescribing for adults with colds, upper respiratory tract infection, and bronchitis by ambulatory care physicians. JAMA 1997; 278: 901-4.

20. Guillemot D. How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemio- logic approach. Clin Microbiol Infect 2001; 7 (Suppl 5): 19-23.

21. Guo D., Cai Y., Chai D. et al. The cardiotoxicity of macrolides: a systematic review. Pharmazie 2010; 65(9): 631-640.

22. Hickner J.M., Bartlett J.G., Besser R.E., et al. Principles of appropriate antibiotic use for acute rhinosinusitis in adults: background. Ann Intern Med 2001; 134 (6): 498-505.

23. http://www.accessdata.fda.gov/ drugsatfda_docs/label/2013/050710s0 39, 050711s036, 050784 s023lbl.pdf.

24. http://www.fda.gov/Drugs/ DrugSafety/DrugSafetyPodcasts/ ucm 343678. htm.

25. L H., Lui D-H., Chen L.-L. et. al. Meta-Analysis of the Adverse Effects of Long-Term Azithromycin Use in Patientswith Chronic Lung Diseases // AntimicrobialAgentsand Chemotherapy. 2014. Vol. 58(1). P. 511-517.

26. Low D.E. Antimicrobial drug use and resistance among respiratory pathogens in the community. Clin Infect Dis 2001; 33 (Suppl 3): S206-13.

27. Mosholder A.D., Mathew J., Alexander J.J. et al. Cardiovascular risks with azithromycin and other antibacterial drugs // N. Engl. J. Med. 2013. Vol. 368. P. 1665-1668.

28. Odenholt-Tornqvist I.,Lowdin E., Cars О. Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens // Antimicrob. Agents Chemother. 1995. Vol. 39. P. 221-226.

29. Paterson J.M., Mamdani M.M., Manno M. et al. Fluoroquinolone therapy and idiosyncratic liver injuri: a population-based study. CMAJ 2012; 184 (14): 1565-70.

30. Peters D.H., Friedel H.A., McTavish D. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drug 1992; 44: 750-99.

31. Plouffe J., Schwartz D., Kolokathis A. et al. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group // Antimicrob. Agents Chemother. 2000. Vol. 44(7). P. 1796-1802.

32. Poluzzi E., Rischi E., Motorola D. et al. Antimicrobial and the risk of torsade de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System // Drug Saf. 2010. Vol. 33(4). P. 303-314.

33. Respiratory tract infections - antibiotic prescribing. Prescribing of antibiotics for self-limiting respiratory tract infections in adults and children in primary care: NICE clinical guideline 69. Developed by the Centre for Clinical Practice at NICE. - Issue date: July 2008. - 122 p.

34. Schlemmer B. Impact of registration procedures on antibiotic polices. Clin Microbiol Infect Dis 2001; 7 (Suppl 6): 5-8.

35. Shryock T.R., Mortensen J.E., Baumholtz M. The effects of macrolides on the expression of bacterial virulence mechanisms // J. Antimicrobial Chemotherapy. 1998. Vol. 41. P. 505-512.

36. Snow V., Gonzales R. Principles of appropriate antibiotic use for treatment of nonspecific upper respiratory tract infections in adults. Ann Intern Med 2001; 134 (6): 487-89.

37. Svanstrom H., Pasternak B., Hviid A. Use of Azithromycin and Death from

Cardiovascular Causes // N. Engl. J. Med. 2013. Vol. 368. P. 1704-1712.

38. Tamaoki J. The effects of macrolides on inflammatory cells. Chest 2004; 125 (Suppl.): 41S-51S.

39. Uzun S., Djamin R.S., Kluytmans Jan A.J.W. et al. Influence of macrolide maintenance therapy and bacterial colonisation on exacerbation frequency and progression of COPD (COLUMBUS): Study protocol for a randomised controlled trial // Trials. 2012 Jun 9. Vol. 13. Р. 82. doi: 10.1186/1745-6215-13-82.

40. Wayne A.R. Azithromycin and the Risk of Cardiovascular Death // N Engl J Med. 2012. Vol. 366. P. 1881-1890.

41. Williams J.D. Evaluation of the safety of macrolides. Int. J. Antimicrob Agents 2001; 18 (Suppl. 1): S77- S81.

42. Williams J.W., Aguilar C., Makela M. et al. Antibiotic therapy for acute sinusitis: a systematic literature review. In: Douglas R, Bridges-Webb C, eds. Acute Respiratory Infections Module of the Cochrane Database of Systematic reviews. The cochrane Library. Oxford: Updated Software; 1997.

43. Wilton L., Kollarova M., Heeley E., Shakir S. Relative risk of vaginal candidiasis after use of antibiotics compared with antidepressants in women: postmarketing surveillance data in England // Drug Saf. 2003. Vol. 26(8). P. 589-597.

44. Zucher D.R., Balk E., Engels E. et al. Agency for Health Care Policy and Research Publication No.99-E016: Evidence Report/Technology Assessment Number 9. Diagnosos and treatment of acute bacterial rhinosinusitis. Available at: www.ahrq.gov/clinic/sinusitis.htm.

Размещено на Allbest.ru

...

Подобные документы

Работы в архивах красиво оформлены согласно требованиям ВУЗов и содержат рисунки, диаграммы, формулы и т.д.
PPT, PPTX и PDF-файлы представлены только в архивах.
Рекомендуем скачать работу.